Free Trial
NASDAQ:MBOT

Microbot Medical Q3 2025 Earnings Results & Report

Microbot Medical logo
$1.07 0.00 (0.00%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.09 +0.02 (+1.87%)
As of 10/9/2026 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Microbot Medical missed analyst earnings expectations in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$0.07 versus the -$0.06 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
7:00 AM ET

Microbot Medical EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.06
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Microbot Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.63 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Microbot Medical's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Microbot Medical Q3 2025 Earnings FAQ

Microbot Medical (NASDAQ:MBOT) reported earnings of -$0.07 per share for Q3 2025, missing the consensus estimate of -$0.06. The report was announced on Wednesday, November 12, 2025.

Microbot Medical's next earnings date is estimated for Wednesday, November 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Microbot Medical on the company's earnings history page.

Microbot Medical Earnings Headlines

First Look: Elon’s “Starphone”
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
Microbot Medical® Highlights Growth Strategy
See More Microbot Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Microbot Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Microbot Medical and other key companies, straight to your email.

About Microbot Medical

Microbot Medical (NASDAQ:MBOT) (NASDAQ: MBOT) is a medical device company developing robotic and computer-assisted technologies for minimally invasive endovascular procedures. The company focuses on systems intended to help physicians navigate blood vessels and deliver interventional devices while potentially improving procedural control and reducing radiation exposure to medical personnel.

Microbot Medical’s primary product candidate is the LIBERTY Endovascular Robotic System, a single-use, disposable robotic platform designed to remotely control guidewires and catheters during vascular procedures. The system is being developed to support treatment in challenging anatomy and to reduce the need for physicians to work directly beside radiation-emitting imaging equipment. LIBERTY remains an investigational device and is subject to applicable regulatory review.

The company has roots in Israel and maintains operations in both Israel and the United States. Microbot Medical is led by Harel Gadot, who serves as chairman, president and chief executive officer. Its technologies are being developed for potential use in interventional radiology, vascular medicine and other endovascular applications.

View Microbot Medical Profile